Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2020-05-13 Earnings Release
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2020, reporting financial results for the first quarter ended March 31, 2020. It includes a press release as an exhibit with the financial results. The text explicitly states that the press release reports financial results for the quarter but does not contain detailed financial statements or substantive financial data itself. The document length is 3889 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. According to the rules, an initial announcement of quarterly financial results with key highlights only is classified as an Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2020-05-13 English
DEFINITIVE ADDITIONAL MATERIALS
Remuneration Information Classification · 95% confidence The document is titled 'DEFA14A' and contains references to 'Definitive Additional Materials' and 'Schedule 14A Information' which are related to proxy statements filed under the Securities Exchange Act of 1934. The presence of terms like 'Proxy Statement' and 'Definitive Additional Materials' indicates this is related to shareholder voting and proxy solicitation materials. The document is not a full proxy statement but additional materials related to it, which aligns with the Remuneration Information or Proxy Solicitation categories. However, since it is a definitive additional material to a proxy statement (Schedule 14A), the most appropriate classification is 'Remuneration Information' (DEF 14A), which covers reports detailing compensation and related proxy materials. The document length is short and does not contain financial statements or earnings data, so it is not an Annual Report or Earnings Release. Therefore, the classification is DEF 14A with high confidence.
2020-04-29 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2020-04-29 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 14, 2020. It references a slide presentation (Exhibit 99.1) to be presented at a virtual healthcare conference by the company's management. The content is primarily an announcement of the presentation event and the attached slides, not a full financial report or earnings release. The document length is 3207 characters, which is relatively short and consistent with an announcement rather than a full report. The key phrase 'slide presentation attached as Exhibit 99.1' and the context of a conference presentation indicate this is an Investor Presentation filing. Therefore, the appropriate classification is Investor Presentation (IP).
2020-04-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes the SEC header, the form type (8-K), and a specific item (Item 8.01 Other Events) describing a delay in clinical trial commencement due to COVID-19. There are no financial statements or detailed financial data present. The document is relatively short (3333 characters) and serves as a regulatory announcement of an event rather than a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-04-01 English
FORM 4 SUBMISSION
Director's Dealing
2020-03-24 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.